HALO
Halozyme Therapeutics Inc
113.90$
-1.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 30.2% | 21.7% | 22.6% | 9.8% | 6.7% | 23.2% | 16.2% | 18.4% | 21.1% | 23.2% | 15.7% | 21.9% | |
| 69.8% | 78.3% | 77.4% | 90.2% | 93.3% | 76.8% | 83.8% | 81.6% | 78.9% | 76.8% | 84.3% | 78.1% | |
| 105.8% | 69.0% | 102.8% | 47.6% | 98.9% | 71.8% | 12.8% | 8.0% | 10.1% | 9.2% | 7.8% | 5.8% | |
| 47.7% | 29.6% | 31.3% | 17.0% | 40.0% | 39.4% | 17.1% | 11.4% | 21.7% | 18.0% | 15.2% | 14.8% | |
| 153.5% | 98.7% | 134.1% | 64.6% | 139.0% | 111.3% | 29.9% | 19.4% | 38.4% | 36.1% | 30.0% | 19.7% | |
| -83.7% | -20.3% | -56.7% | 25.6% | -45.7% | -34.5% | 53.9% | 62.2% | 40.5% | 40.7% | 54.3% | 58.4% | |
| 7.4% | 3.9% | 13.6% | 6.9% | 11.9% | 5.9% | 7.6% | 1.7% | 2.6% | 2.3% | 1.8% | 1.3% | |
| -90.8% | -23.9% | -69.4% | 19.5% | -52.5% | -36.9% | 48.3% | 56.1% | 37.7% | 42.0% | 54.9% | 33.4% | |
| 5.1% | 2.6% | 0.8% | -0.4% | 0.4% | 0.0% | 0.1% | -34.8% | 7.1% | 8.0% | 11.1% | 10.7% | |
| -90.8% | -23.9% | -70.2% | 19.9% | -52.9% | -36.9% | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% | |
| -81.3% | -19.1% | -55.1% | 26.3% | -44.1% | -32.4% | 55.1% | 62.9% | 47.8% | 54.5% | 64.7% | 41.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.